PEDIATRICS Vol. 88 No. 3 September 1991, pp. 552
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by L., J. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by L., J. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

COMPETITORS' DRUGS BATTLE SEPTIC SHOCK

J. F. L. MD

Two competitors, Centocor Inc. and Xoma Corp., are seeking clearance from the Food and Drug Administration for an entirely new sort of anti-infection drug...

The new drugs, unlike antibiotics that act upon the bacteria, latch on to toxins made by the bacteria, thus blocking the next biochemical step in the disease process. Both drugs are monoclonal antibodies, proteins that zero in on selected targets in the body. Centoxin is derived from human spleen cells; Xoma's drug, called Xomen E-5, from mouse spleen cells.

... Some estimates... put the combined U.S. and European sales for both drugs at $750 million by the mid-1990s.

One reason for the jumbo market projections is sky-high prices for drugs produced by biotechnology. Centoxin and Xomen-E5 both are expected to cost between $1,500 and $2,500 for a single course of treatment, given by injection.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?